ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
April 12, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 11, 2023 07:00 ET
|
ONL Therapeutics
Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
February 13, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
February 02, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
February 01, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
January 26, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Outlook on the Diabetic Retinopathy Global Market to 2027 - Rising Number of Diabetic Patients is Driving Growth
November 14, 2022 04:13 ET
|
Research and Markets
Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report By Type, By Treatment Type, By Regional Outlook and Forecast,...
Global Retinal Surgery Devices Market Analysis Report 2022: A $3.7 Billion Market by 2027 - Consistent Efforts by Healthcare Organizations to Fuel the Market
September 26, 2022 08:18 ET
|
Research and Markets
Dublin, Sept. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy...
Global Nonmydriatic Handheld Fundus Cameras Market to Reach $192.6 Million by 2026
September 09, 2022 04:13 ET
|
Research and Markets
Dublin, Sept. 09, 2022 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.Global...
Outlook on the Ophthalmoscopes Global Market to 2027 - Rise in Eye Disorder Prevalence & Surgical Procedures is Driving Growth
July 07, 2022 05:03 ET
|
Research and Markets
Dublin, July 07, 2022 (GLOBE NEWSWIRE) -- The "Ophthalmoscopes Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. Ophthalmoscope...